Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).
Publication details: 2017Description: 8019-8019ISSN:- 0732183X
- Journal of Clinical Oncology
No physical items for this record
There are no comments on this title.
Log in to your account to post a comment.